Research

The case for biosimilars

An organized group of pills
Photo: Dwight Eschliman/Getty Images

It's too soon to throw in the towel on biosimilars, especially because there's evidence that they're lowering the net costs of biologics, Alex Brill and Benedic Ippolito of the American Enterprise Institute argue in a Health Affairs blog.

Why it matters: The authors were refuting an April post in Health Affairs that argued biologics are a natural monopoly, so biosimilars aren't going to work.

Another century of gender inequality in computer science

Reproduced from Wang et al., 2019, "Gender Trends in Computer Science Authorship" ; Chart: Axios Visuals

Female researchers, for decades largely boxed out of computer science, have in recent years entered the field in record numbers, but new research suggests the current rate of change is not nearly rapid enough to bring parity to the field within a lifetime.

Why it matters: The direction of computer science research is determined by the people who make up the field.